Scarica l'app Stockscreener
101.50
0.14%
0.14
Precedente Chiudi:
$101.36
Aprire:
$101.4
Volume 24 ore:
2.73M
Relative Volume:
0.54
Capitalizzazione di mercato:
$19.26B
Reddito:
$2.83B
Utile/perdita netta:
$-1.02B
Rapporto P/E:
-18.42
EPS:
-5.51
Flusso di cassa netto:
$194.14M
1 W Prestazione:
+0.44%
1M Prestazione:
+48.46%
6M Prestazione:
+87.93%
1 anno Prestazione:
+62.37%
Intervallo 1D:
$101.38
$101.61
Intervallo di 1 settimana:
$100.95
$101.95
Portata 52W:
$38.81
$101.95
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Confronta EXAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
101.50 | 19.23B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
572.28 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.33 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.20 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
139.68 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.26 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
EXAS Quantitative Stock Analysis - Nasdaq
Why Exact Sciences Stock Surged Today - AOL.com
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS - The AI Journal
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect - Business Wire
Quantbot Technologies LP Invests $604,000 in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences stock reaches 52-week high at 101.89 USD By Investing.com - Investing.com South Africa
Exact Sciences stock reaches 52-week high at 101.89 USD - Investing.com
1 Healthcare Stock for Long-Term Investors and 2 We Avoid - Finviz
Exact Sciences Showcases Breadth of Early Detection and Treatmen - GuruFocus
Peninsula company rides blank check to Wall Street after raising more than $1 billion as a startup - The Business Journals
Baird Financial Group Inc. Sells 30,218 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Assessing Exact Sciences After 77.5% YTD Surge and Abbott Deal Outlook - Yahoo Finance
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Cancer detection firm Freenome to go public via $330 million SPAC deal - statnews.com
Cancer blood test maker Freenome going public with $330M SPAC - BioWorld MedTech
Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk - simplywall.st
Has Exact Sciences Rally of Over 50% Left Room for Further Upside? - simplywall.st
OMERS ADMINISTRATION Corp Sells 113,387 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Published on: 2025-12-04 02:35:05 - Newser
Why Is Exact Sciences (EXAS) Up 45.4% Since Last Earnings Report? - Yahoo Finance
Schroder Investment Management Group Raises Stock Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Exact Sciences (NASDAQ:EXAS) Sees Large Volume IncreaseHere's Why - MarketBeat
Top 2 Health Care Stocks You May Want To Dump This Month - Benzinga
Why Exact Sciences Corporation (EXK) stock gets analyst attentionCEO Change & Momentum Based Trading Signals - Newser
Mackenzie Financial Corp Has $151.76 Million Stock Position in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now - ts2.tech
Stifel downgrades Exact Sciences stock rating to Hold following Abbott acquisition news - Investing.com
UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition - Insider Monkey
Aug EndMonth: How Exact Sciences Corporation stock performs after earningsJuly 2025 Final Week & Reliable Entry Point Trade Alerts - BỘ NỘI VỤ
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerEXAS, SEE, CDTX, and MRSN - The Malaysian Reserve
Exact Sciences Corporation $EXAS Shares Acquired by Magnetar Financial LLC - MarketBeat
Here Are Tuesday's Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More - 24/7 Wall St.
Exact Sciences (EXAS): Assessing Valuation After a 56% One-Month Rally - Yahoo Finance
Roche collaboration to accelerate Freenome’s blood-based cancer screening - Mugglehead Magazine
This Coinbase Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More - AOL.com
Exact Sciences (EXAS) Downgraded by Canaccord Genuity, PT Raised to $105 | EXAS Stock News - GuruFocus
Champlain Investment Partners LLC Has $134.44 Million Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Canaccord Genuity downgrades Exact Sciences stock to Hold after Abbott deal - Investing.com
Halper Sadeh LLC Encourages GDOT, BLFY, EXAS Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Exact Sciences stock rating downgraded to Hold by TD Cowen following Abbott deal - Investing.com
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium - Business Wire
UBS raises Exact Sciences stock price target to $105 on Abbott deal - Investing.com
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare
Exact Sciences (EXAS) Downgraded to Hold by Benchmark Analyst | - GuruFocus
Here are Monday’s Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More - MSN
Exact Sciences (EXAS) Receives Downgrade from Jefferies Amidst P - GuruFocus
Here are Monday's Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More - 24/7 Wall St.
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Jefferies downgrades Exact Sciences stock to Hold after Abbott acquisition - Investing.com
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):